Related Experiment Video

Updated: Dec 8, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K

MOB1 Inhibits Malignant Progression of Colorectal Cancer by Targeting PAK2

Jie Liu1, Zhitao Shi2, Yunyun Ma1

  • 1Department of Proctology, Affiliated Traditional Chinese Medicine Hospital, Xinjiang Medical University, Urumqi, People's Republic of China.

Oncotargets and Therapy
|September 18, 2020
PubMed
Abstract

Insights

Low MOB1 expression in colorectal cancer (CRC) accelerates tumor growth and metastasis by modulating PAK2. This finding offers new insights for CRC diagnosis and treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Colorectal cancer (CRC) remains a significant global health challenge.
  • Understanding the molecular mechanisms underlying CRC proliferation and metastasis is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the role of MOB1 in inhibiting colorectal cancer (CRC) proliferation and metastasis.
  • To elucidate the mechanism by which MOB1 affects CRC progression.
  • To provide guidance for the early diagnosis and treatment of CRC.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qRT-PCR) to assess MOB1 expression in CRC tissues.
  • Cell Counting Kit (CCK-8) and Transwell assays to evaluate cell proliferation and migration.
  • Luciferase assay, qRT-PCR, and Western Blot to investigate the interaction between MOB1 and PAK2.

Main Results:

  • MOB1 expression was significantly lower in CRC tissues compared to adjacent tissues.
  • Low MOB1 expression correlated with increased metastasis and poorer prognosis in CRC patients.
  • Overexpression of MOB1 inhibited CRC cell proliferation and migration, while MOB1 knockdown enhanced these processes.
  • MOB1 was found to interact with PAK2, negatively regulating its expression and affecting CRC cell behavior.

Conclusions:

  • Reduced MOB1 expression in colorectal cancer promotes tumor proliferation and migration.
  • The mechanism involves MOB1 modulating PAK2 expression.
  • These findings highlight MOB1 as a potential therapeutic target and biomarker for CRC.
Keywords:
CRCMOB1PAK2malignant progression

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K